Charles Bennett to Neutropenia
This is a "connection" page, showing publications Charles Bennett has written about Neutropenia.
Connection Strength
4.164
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.604
-
Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst. 2013 Aug 07; 105(15):1072-3.
Score: 0.409
-
Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 07 18; 369(3):286.
Score: 0.409
-
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
Score: 0.400
-
Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007 Aug; 12(8):1019-26.
Score: 0.271
-
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug; 40(3):185-92.
Score: 0.268
-
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007 Apr; 12(4):478-83.
Score: 0.264
-
Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007; 30(4):295-306.
Score: 0.260
-
When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol. 2006 Jul 01; 24(19):2975-7.
Score: 0.248
-
Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol. 2005 Oct 01; 23(28):6822-5.
Score: 0.237
-
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. Pharmacoeconomics. 2005; 23(8):767-75.
Score: 0.226
-
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 2000 Feb; 34(2):92-6.
Score: 0.161
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992 Feb 01; 116(3):177-82.
Score: 0.092
-
Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
Score: 0.075
-
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202.
Score: 0.065
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
Score: 0.062
-
Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer. Crit Rev Oncol Hematol. 2003 Oct 15; 48(Suppl):S71-4.
Score: 0.052
-
Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? Drugs Aging. 2003; 20(7):479-83.
Score: 0.049
-
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 Oct 15; 18(20):3558-85.
Score: 0.011